Compare Bristol-Myers Squibb Co (BMY) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares Global Clean Energy ETF — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while iShares Global Clean Energy ETF trades at $19.2. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares Global Clean Energy ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| BMY | ICLN | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $23.75 |
52-Week Low | $42.60 | $13.41 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
ICLN, the iShares Global Clean Energy ETF, trades at $18.625, down 3.25% on the day, with technical indicators showing a bearish trend. The ETF holds 105 global renewable energy companies and has delivered strong year-to-date performance, driven by increased energy demand and policy support. Recent news highlights comparisons with traditional energy and uranium ETFs, emphasizing ICLN's growth focus versus income alternatives.
Outlook remains mixed: clean energy benefits from structural trends like AI-driven power demand and global decarbonization goals, but risks include regulatory uncertainty and high volatility. The ETF's valuation and growth potential appeal to long-term investors, though near-term price action suggests caution amid bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
